ATE398107T1 - N-pyrrolidin-3-yl-amide-derivate als inhibitoren der serotonin- und noradrenalin-wiederaufnahme - Google Patents

N-pyrrolidin-3-yl-amide-derivate als inhibitoren der serotonin- und noradrenalin-wiederaufnahme

Info

Publication number: ATE398107T1
Authority: AT; Austria
Prior art keywords: reuppost; noradrenaline; serotonin; pyrrolidine; inhibitors
Prior art date: 2003-06-17

Application number

AT04736241T

Other languages

English (en)

Inventor

Paul Vincent Fish

Michael Jonathan Fray

Alan Stobie

Florian Wakenhut

Gavin WHITLOCK

Alan Daniel Brown

Mark David Andrews

Mark Lansdell

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-17

Filing date

2004-06-07

Publication date

2008-07-15

2003-06-17 Priority claimed from GBGB0314048.0A external-priority patent/GB0314048D0/en

2004-06-07 Application filed by Pfizer filed Critical Pfizer

2008-07-15 Application granted granted Critical

2008-07-15 Publication of ATE398107T1 publication Critical patent/ATE398107T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Addiction (AREA)
Psychology (AREA)
Gynecology & Obstetrics (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Hematology (AREA)
Anesthesiology (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrrole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)

AT04736241T 2003-06-17 2004-06-07 N-pyrrolidin-3-yl-amide-derivate als inhibitoren der serotonin- und noradrenalin-wiederaufnahme ATE398107T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0314048.0A GB0314048D0 (en)	2003-06-17	2003-06-17	Novel compounds
US49312603P	2003-08-06	2003-08-06

Publications (1)

Publication Number	Publication Date
ATE398107T1 true ATE398107T1 (de)	2008-07-15

Family

ID=33554153

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04736241T ATE398107T1 (de)	2003-06-17	2004-06-07	N-pyrrolidin-3-yl-amide-derivate als inhibitoren der serotonin- und noradrenalin-wiederaufnahme

Country Status (31)

Country	Link
US (2)	US7378436B2 (de)
EP (1)	EP1638933B1 (de)
JP (1)	JP4137159B2 (de)
KR (1)	KR100803796B1 (de)
AP (1)	AP2005003467A0 (de)
AR (1)	AR044715A1 (de)
AT (1)	ATE398107T1 (de)
AU (1)	AU2004247487B2 (de)
BR (1)	BRPI0411594A (de)
CA (1)	CA2530159C (de)
CY (1)	CY1110434T1 (de)
DE (1)	DE602004014372D1 (de)
DK (1)	DK1638933T3 (de)
EA (1)	EA009881B1 (de)
EC (1)	ECSP056232A (de)
ES (1)	ES2305776T3 (de)
HR (2)	HRP20050993A2 (de)
IL (1)	IL172063A0 (de)
IS (1)	IS8136A (de)
MA (1)	MA27885A1 (de)
MX (1)	MXPA05013960A (de)
NL (1)	NL1026438C2 (de)
NZ (1)	NZ544046A (de)
PA (1)	PA8605301A1 (de)
PE (1)	PE20050631A1 (de)
PL (1)	PL1638933T3 (de)
PT (1)	PT1638933E (de)
SI (1)	SI1638933T1 (de)
TW (1)	TW200505852A (de)
UY (1)	UY28360A1 (de)
WO (1)	WO2004110995A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100888275B1 (ko) *	2000-07-31	2009-03-10	니코메드 댄마크 에이에스	코 투여용 펜타닐 조성물
KR100803796B1 (ko) *	2003-06-17	2008-02-14	화이자 인코포레이티드	세로토닌 및 노르아드레날린 재흡수 억제제로서의ｎ-피롤리딘-3-일-아미드 유도체
BRPI0516602A (pt)	2004-10-18	2008-09-16	Lilly Co Eli	composto, e, composição farmacêutica
GB0425766D0 (en) *	2004-11-23	2004-12-22	Pfizer Ltd	Novel compounds
US7122683B2 (en)	2004-11-23	2006-10-17	Pfizer Inc.	Amides useful as monoamine re-uptake inhibitors
CA2590226A1 (en) *	2004-12-14	2006-06-22	Pfizer Limited	N-pyrrolidin-3yl-amide derivatives as serotonin and noradrenalin re-uptake inhibitors
WO2006064336A2 (en) *	2004-12-14	2006-06-22	Pfizer Limited	N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenalin re-uptake inhibitors
TWI410406B (zh) *	2005-05-13	2013-10-01	Otsuka Pharma Co Ltd	吡咯烷化合物
KR100962732B1 (ko)	2005-06-02	2010-06-09	에프. 호프만-라 로슈 아게	피페리딘-4-일-아마이드 유도체 및 ｓｓｔ 수용체 아형 5길항제로서 그의 용도
WO2007135530A2 (en) *	2006-05-22	2007-11-29	Pfizer Limited	Pharmaceutically & veterinarily suitable salt
US20080014152A1 (en) *	2006-07-13	2008-01-17	Di Mauro Thomas M	Intranasal delivery of clenbuterol across the cribriform plate and into the brain
JP5219465B2 (ja) *	2006-11-10	2013-06-26	大塚製薬株式会社	医薬
EP2119702A4 (de) *	2007-01-31	2010-12-08	Dainippon Sumitomo Pharma Co	Amidderivat
JP2010189275A (ja) *	2007-06-14	2010-09-02	Dainippon Sumitomo Pharma Co Ltd	ナフタレン誘導体
US8263652B2 (en)	2007-10-31	2012-09-11	Sk Biopharmaceuticals Co., Ltd.	Stabilized pediatric suspension of carisbamate
JP5484069B2 (ja) *	2007-12-19	2014-05-07	大日本住友製薬株式会社	二環性へテロ環誘導体
US7888386B2 (en) *	2008-07-24	2011-02-15	Theravance, Inc.	3-(phenoxyphenylmethyl)pyrrolidine compounds
EP2358676B1 (de)	2008-11-14	2012-10-10	Theravance, Inc.	Ktistalline Form einer 4-[2-(2-Fluorphenoxymethyl)phenyl]piperidinverbindung
JP2012524098A (ja) *	2009-04-15	2012-10-11	セラヴァンス，インコーポレーテッド	３−（フェノキシピロリジン−３−イル−メチル）ヘテロアリール、３−（フェニルピロリジン−３−イルメトキシ）ヘテロアリールおよび３−（ヘテロアリールピロリジン−３−イルメトキシ）ヘテロアリール化合物
US8658639B2 (en)	2009-06-24	2014-02-25	Dainippon Sumitomo Pharma Co., Ltd	N-substituted-cyclic amino derivative
RU2535669C2 (ru) *	2009-07-13	2014-12-20	Тереванс, Инк.	3-феноксиметилпирролидиновые соединения
JP5714580B2 (ja)	2009-07-21	2015-05-07	セラヴァンスバイオファーマアール＆ディーアイピー，エルエルシー	３−フェノキシメチルピロリジン化合物
WO2011085291A1 (en)	2010-01-11	2011-07-14	Theravance, Inc.	1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
ES2543064T3 (es) *	2010-03-22	2015-08-14	Theravance Biopharma R&D Ip, Llc	Compuestos de 1-(2-fenoximetilheteroaril)piperidina y piperazina
US8471040B2 (en)	2010-10-11	2013-06-25	Theravance, Inc.	Serotonin reuptake inhibitors
US8501964B2 (en)	2010-12-03	2013-08-06	Theravance, Inc.	Serotonin reuptake inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE138773C (de)
US3963745A (en)	1972-04-03	1976-06-15	A. H. Robins Company, Incorporated	Method for controlling emesis with N-(1-substituted-3-pyrrolidinyl)benzamides and thiobenzamides
US4002757A (en) *	1974-12-26	1977-01-11	A. H. Robins Company, Incorporated	N-(1-substituted-3-pyrrolidinyl)-4-quinolinecarboxamides
US4020072A (en) *	1976-05-04	1977-04-26	E. R. Squibb & Sons, Inc.	5-Aminomethyl-1H-pyrazolo[3,4-b]pyridines
GB1574419A (en) *	1977-11-11	1980-09-03	Anphar Sa	Piperidine compounds
CH628885A5 (en) *	1978-01-01	1982-03-31	Anphar Sa	Piperidine derivative
US5130312A (en) *	1987-07-17	1992-07-14	Janssen Pharmaceutica N.V.	Substituted N-(3-hydroxy-4-piperidinyl)benzamides
FR2642069B1 (fr) *	1989-01-20	1991-04-12	Rhone Poulenc Sante	Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent
WO1997018813A1 (en)	1995-11-22	1997-05-29	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
AU4167099A (en)	1998-06-19	2000-01-05	Nissan Chemical Industries Ltd.	Heterocyclic compounds as hypoglycemic agents
US6670299B1 (en) *	1999-07-03	2003-12-30	Northwestern University	Cyclopentadienyl-containing low-valent early transition metal olefin polymerization catalysts
FR2802206B1 (fr) *	1999-12-14	2005-04-22	Sod Conseils Rech Applic	Derives de 4-aminopiperidine et leur utilisation en tant que medicament
EP2140868A1 (de)	2000-03-03	2010-01-06	Eisai R&D Management Co., Ltd.	Verwendung eines Cholinesterasehemmers zur Behandlung von Demenz und Beinträchtigung der Wahrnehmung assoziiert mit oder verursacht durch eine Chemotherapie
RU2398765C1 (ru) *	2000-03-06	2010-09-10	Акадиа Фармасьютикалз, Инк.	Азациклические соединения для применения при лечении опосредованных серотонином заболеваний
WO2002024694A1 (en)	2000-09-22	2002-03-28	Smithkline Beecham, P.L.C.	Pyrazolopyridines and pyrazolopyridazines as antidiabetics
HUP0303360A2 (hu)	2000-09-25	2004-01-28	Actelion Pharmaceuticals Ltd.	Maláriaellenes hatású szubsztituált amino-aza-cikloalkánok és ezeket tartalmazó gyógyszerkészítmények
JP4619655B2 (ja)	2001-09-14	2011-01-26	ハイ・ポイント・ファーマスーティカルズ、エルエルシー	新規アミノアゼチジン、−ピロリジンおよび−ピペリジン誘導体
WO2003037865A1 (en)	2001-10-31	2003-05-08	Morphochem Aktiengesellschaft für kombinatorische Chemie	Novel anticancer compounds
GB0128287D0 (en)	2001-11-26	2002-01-16	Smithkline Beecham Plc	Novel method and compounds
WO2004000808A2 (en) *	2002-06-24	2003-12-31	Acadia Pharmaceuticals Inc.	N-substituted piperidine derivatives as serotonin receptor agents
AU2003249983A1 (en)	2002-07-18	2004-02-09	Actelion Pharmaceuticals Ltd	Piperidines useful for the treatment of central nervous system disorders
WO2004022536A1 (en)	2002-09-04	2004-03-18	Glenmark Pharmaceuticals Limited	New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
ES2323528T3 (es)	2002-12-20	2009-07-20	Chemocentryx, Inc.	Inhibidores de la union de la quimiokina sdf-o i-tac al receptor ccxckr2.
KR100803796B1 (ko) *	2003-06-17	2008-02-14	화이자 인코포레이티드	세로토닌 및 노르아드레날린 재흡수 억제제로서의ｎ-피롤리딘-3-일-아미드 유도체

2004
- 2004-06-07 KR KR1020057024147A patent/KR100803796B1/ko not_active IP Right Cessation
- 2004-06-07 NZ NZ544046A patent/NZ544046A/en unknown
- 2004-06-07 MX MXPA05013960A patent/MXPA05013960A/es active IP Right Grant
- 2004-06-07 PT PT04736241T patent/PT1638933E/pt unknown
- 2004-06-07 SI SI200430767T patent/SI1638933T1/sl unknown
- 2004-06-07 AU AU2004247487A patent/AU2004247487B2/en not_active Expired - Fee Related
- 2004-06-07 EP EP04736241A patent/EP1638933B1/de not_active Expired - Lifetime
- 2004-06-07 AT AT04736241T patent/ATE398107T1/de not_active IP Right Cessation
- 2004-06-07 JP JP2006516540A patent/JP4137159B2/ja not_active Expired - Fee Related
- 2004-06-07 ES ES04736241T patent/ES2305776T3/es not_active Expired - Lifetime
- 2004-06-07 WO PCT/IB2004/001943 patent/WO2004110995A1/en active IP Right Grant
- 2004-06-07 DE DE602004014372T patent/DE602004014372D1/de not_active Expired - Lifetime
- 2004-06-07 DK DK04736241T patent/DK1638933T3/da active
- 2004-06-07 AP AP2005003467A patent/AP2005003467A0/xx unknown
- 2004-06-07 BR BRPI0411594-5A patent/BRPI0411594A/pt not_active IP Right Cessation
- 2004-06-07 EA EA200501730A patent/EA009881B1/ru not_active IP Right Cessation
- 2004-06-07 CA CA002530159A patent/CA2530159C/en not_active Expired - Fee Related
- 2004-06-07 PL PL04736241T patent/PL1638933T3/pl unknown
- 2004-06-14 PE PE2004000590A patent/PE20050631A1/es not_active Application Discontinuation
- 2004-06-14 UY UY28360A patent/UY28360A1/es not_active Application Discontinuation
- 2004-06-16 AR ARP040102082A patent/AR044715A1/es not_active Application Discontinuation
- 2004-06-16 PA PA20048605301A patent/PA8605301A1/es unknown
- 2004-06-16 TW TW093117317A patent/TW200505852A/zh unknown
- 2004-06-17 US US10/872,160 patent/US7378436B2/en not_active Expired - Fee Related
- 2004-06-17 NL NL1026438A patent/NL1026438C2/nl not_active IP Right Cessation
2005
- 2005-11-20 IL IL172063A patent/IL172063A0/en unknown
- 2005-11-21 IS IS8136A patent/IS8136A/is unknown
- 2005-12-14 HR HR20050993A patent/HRP20050993A2/hr not_active Application Discontinuation
- 2005-12-16 EC EC2005006232A patent/ECSP056232A/es unknown
- 2005-12-16 MA MA28674A patent/MA27885A1/fr unknown
2008
- 2008-05-21 US US12/124,755 patent/US20080306123A1/en not_active Abandoned
- 2008-07-09 HR HR20080339T patent/HRP20080339T3/xx unknown
- 2008-08-14 CY CY20081100869T patent/CY1110434T1/el unknown

Also Published As

Publication number	Publication date
AR044715A1 (es)	2005-09-21
WO2004110995A1 (en)	2004-12-23
IL172063A0 (en)	2009-02-11
WO2004110995A8 (en)	2005-04-21
NL1026438C2 (nl)	2005-09-20
SI1638933T1 (sl)	2008-10-31
ECSP056232A (es)	2006-04-19
EA200501730A1 (ru)	2006-08-25
IS8136A (is)	2005-11-21
PE20050631A1 (es)	2005-09-14
EP1638933A1 (de)	2006-03-29
HRP20050993A2 (en)	2006-03-31
JP2006527758A (ja)	2006-12-07
CA2530159C (en)	2010-02-02
AU2004247487A1 (en)	2004-12-23
DK1638933T3 (da)	2008-07-28
MA27885A1 (fr)	2006-05-02
US7378436B2 (en)	2008-05-27
CA2530159A1 (en)	2004-12-23
DE602004014372D1 (de)	2008-07-24
PL1638933T3 (pl)	2008-10-31
UY28360A1 (es)	2005-01-31
TW200505852A (en)	2005-02-16
PA8605301A1 (es)	2005-02-04
KR20060036927A (ko)	2006-05-02
US20050137229A1 (en)	2005-06-23
PT1638933E (pt)	2008-07-22
NL1026438A1 (nl)	2004-12-20
EP1638933B1 (de)	2008-06-11
KR100803796B1 (ko)	2008-02-14
MXPA05013960A (es)	2006-02-24
JP4137159B2 (ja)	2008-08-20
CY1110434T1 (el)	2015-04-29
EA009881B1 (ru)	2008-04-28
AU2004247487B2 (en)	2010-05-20
AP2005003467A0 (en)	2006-12-31
ES2305776T3 (es)	2008-11-01
NZ544046A (en)	2009-08-28
US20080306123A1 (en)	2008-12-11
BRPI0411594A (pt)	2006-08-29
HRP20080339T3 (en)	2008-08-31

Publication	Publication Date	Title
ATE398107T1 (de)	2008-07-15	N-pyrrolidin-3-yl-amide-derivate als inhibitoren der serotonin- und noradrenalin-wiederaufnahme
DE602004008303D1 (de)	2007-09-27	Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
DE602005025733D1 (de)	2011-02-17	Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase
DE502005011241D1 (de)	2011-05-26	Indazolderivate als inhibitoren der hormon-sensitiven lipase
DE60325032D1 (de)	2009-01-15	2-hydroxy-3-heteroarylindole derivate als gsk3 inhibitoren
ATE386730T1 (de)	2008-03-15	Phenylpiperazinderivate als serotonin wiederaufnahmehemmer
ATE404564T1 (de)	2008-08-15	Diazepinoindolderivate als kinaseinhibitoren
NL1027811A1 (nl)	2005-06-21	Heterocyclische aminen als remmers 11- -hydroxy-steroïd-dehydrogenase type 1.
CY2013042I2 (el)	2015-12-09	Αναστολεις πυριδυλιου της σηματοδοτησης hedgehog
ATE426599T1 (de)	2009-04-15	Thiazolylpiperidin derivate als mtp inhibitoren
DE60315516D1 (de)	2007-09-20	Pyridazinon-derivate als cdk2-hemmer
NO20045220L (no)	2005-01-19	Heterocykliske inhibitorer for kinaser
DE60321808D1 (de)	2008-08-07	Flavon derivate als inhibitoren von cyclin-abhängigen kinasen
ATE402934T1 (de)	2008-08-15	Malonamidderivate als gamma-secretaseinhibitoren
CY2017048I2 (el)	2018-09-05	Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης
NO20054880D0 (no)	2005-10-21	Azaspiroalkanderivater som inhibitorer av metallproeaser
DE602005023266D1 (de)	2010-10-14	Azabenzofuransubstituierte thioharnstoffe als inhibitoren der virusreplikation
DE602005014646D1 (de)	2009-07-09	Substituierte propenylpiperazinderivate als neue inhibitoren von histondeacetylase
ATE499096T1 (de)	2011-03-15	Kombination von serotonin-wiederaufnahme-hemmern und agomelatin
DE60328978D1 (de)	2009-10-08	Isochinolinderivate als mao-b inhibitoren
ATE430726T1 (de)	2009-05-15	N-acylamino-benzyletherderivate als selektive inhibitoren der monoaminoxidase b
ATE382048T1 (de)	2008-01-15	Pyrazolopyrimdine als hemmstoffe cyclin abhängiger kinasen
DE60302152D1 (de)	2005-12-08	Diaminothiazole und ihre anwendung als cdk4 inhibitoren
DE602004006627D1 (de)	2007-07-05	Nicotinamid-derivate verwendbar als pde4 inhibitoren
ATE449633T1 (de)	2009-12-15	Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern

Legal Events

Date	Code	Title	Description
2008-11-15	UEP	Publication of translation of european patent specification	Ref document number: 1638933 Country of ref document: EP
2012-03-15	REN	Ceased due to non-payment of the annual fee

Date

Code

Title

Description

2008-11-15

UEP

Publication of translation of european patent specification

Ref document number: 1638933

Country of ref document: EP

2012-03-15

REN

Ceased due to non-payment of the annual fee